Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
Highlight
– The endTB-Q phase 3 trial evaluated an all-oral regimen combining bedaquiline, delamanid, linezolid, and clofazimine (BDLC) in patients with rifampicin-resistant and fluoroquinolone-resistant tuberculosis.
– The BDLC regimen demonstrated favourable treatment outcomes comparable to the WHO-recommended standard of care but did not establish overall non-inferiority.
– Safety profiles were similar across the BDLC and control groups, with high rates of grade 3 or higher adverse events in both arms.
– Findings suggest that pre-XDR tuberculosis may require prolonged, reinforced treatment regimens beyond shortened ones.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.